Cellular senescence has been proposed to be an in vitro and in vivo block that cells must overcome in order to immortalize and become tumorigenic. To characterize these pathways, we focused on changes in the cyclindependent kinase inhibitors and their binding partners that underlie the cell cycle arrest at senescence. As a model, we utilized normal human prostate epithelial cell (HPEC) and human uroepithelial cell (HUC) cultures. After 30 ± 40 population doublings cells became growtharrested in G0/1 with a threefold decrease in Cdk2-associated activity, a point de®ned as pre-senescence. Temporally following this growth arrest, the cells develop a senescence morphology and express senescenceassociated b-galactosidase (SA-b-gal 
Introduction
Primary cells derived from most tissues have a ®nite life span, doubling only 50 ± 100 times (Hay¯ick, 1965) . During the initial stages in culture, primary cells grow exponentially, however unlike immortalized cells, growth gradually slows. These cells become irreversibly arrested, yet remain metabolically active. The majority of studies have used normal diploid ®broblasts as a model to study senescence. However, most cancers are of epithelial origin (Greenlee et al., 2001) , including prostate and bladder tumors. Notably, primary prostate and non-invasive bladder tumors retain the ability to senesce in culture (Bright et al., 1997; Yeager et al., 1998) . In contrast, selected metastatic prostate tumors (*20%) can be propagated as xenografts inde®nitely (Klein et al., 1997) and all muscle-invasive bladder cancers with high metastatic potential bypass senescence and spontaneously form cell lines (Yeager et al., 1998) . Thus senescence represents a barrier to tumor formation and bypassing senescence is a phenotype associated with advanced cancer progression in vivo (Campisi, 2000; Serrano et al., 1997; Yeager et al., 1998) .
Based on cell fusion, chromosome transfer, and gene re-expression studies multiple pathways, at least four, must be inactivated to bypass senescence (Ran and Pereira-Smith, 2000; Sasaki et al., 1994) . One locus critical for senescence, identi®ed by chromosome transfer, is on 9p (England et al., 1996) . Our work and others have shown that p16 overexpression, found in this region, plays a critical role in the growth arrest of normal epithelial cells associated with senescence (Jarrard et al., 1999; Rezniko et al., 1996; Sandhu et al., 2000) . p16 shares a common locus with p14 ARF which, when overexpressed, can also induce senescence (Dimri et al., 2000) . Because p14 ARF alters p53 and p21 functions, all of these genes may represent a single pathway important in the induction and maintenance of senescence. Other putative senescence loci frequently altered in cancer include chromosome 6 (Sandhu et al., 2000) and a telomerase inhibiting gene on chromosome 3 (Tanaka et al., 1998) . In human papillomavirus (HPV) 16 E6 or E7 immortalized human prostate epithelial cells (HPECs), the inactivation of p16 or pRb is necessary, but not sucient, for overcoming senescence (Jarrard et al., 1999) . Alterations at other loci are required, including 20 q and 8 p gains and 10 p losses.
In mammalian cells, proliferation control is primarily achieved in the G1-phase of the cell cycle (Pardee, 1989) , the point at which senescent cells arrest. Unless met by a catastrophic occurrence, such as DNA damage, the cell commits itself to replication through a full cycle after passing this point. Progression through late G1 is characterized by the hyperphosphorylation of pRB which releases E2F transcription factors to induce production of gene products necessary for DNA synthesis (Kaelin, 1999; Weinberg, 1995) . Activity of both cdk4/6 complexed with type D cyclins and cyclin E-cdk2 act to phosphorylate pRB rendering it unable to bind various transcription factors leading to the irreversible progression into late G1. Progression through the cell cycle requires the coordinated eorts of several cyclin/cyclin-dependent kinase (cdk) complexes (reviewed in Sherr and Roberts, 1999) . The activity of each complex depends on several factors including the formation of the correct cyclincdk partner, the phosphorylation status of speci®c cdk residues and the levels of cdk inhibitors (CDKIs) (Solomon and Kaldis, 1998) .
The CDKIs include the INK4 (p15  INK4b , p16  INK4a ,  p18  INK4c and p19  INK4d ) and CIP/KIP (p21  CIP1 , p27   KIP1 and p57 KIP2 ) families. INK4 gene products bind directly to cdk4 or cdk6, preventing association of D type cyclins and kinase activity. CIP/KIP proteins bind to cyclin-cdk complexes and are necessary for full activation of cyclin D:cdk4 activity, but are inhibitory when bound to cyclin E:cdk2 and cyclin A:cdk2 complexes (Cheng et al., 1999) . One recently described CIP/KIP member is p57, a gene that demonstrates strict tissue-speci®c expression during development (Nagahama et al., 2001) and is important in the dierentiation of selected cell types (Fink and LeBien, 2001) . The ®ndings of p57 mutations in sporadic cancers and the Beckwith-Wiedemann syndrome suggest it is a candidate tumor suppressor gene (Zhang et al., 1997) . Since CDKIs are critical in G1 regulation they may represent important factors in the growth arrest seen in senescence and, furthermore, represent putative targets for inactivation during immortalization.
It is our goal to understand pathways involved in controlling the senescence growth arrest in HPECs and HUCs and their role in immortalization. We analysed cell cycle position, cdk activity, and the steady-state protein and RNA levels of cyclins, cdks and cdk inhibitors involved in the transition from the G1 to S phase. We focused on several important timepoints in these processes. The ®rst is when cells are growing exponentially (i.e. proliferating) at initial passage. The second occurs when proliferative growth is halted, but cells do not yet express the morphologic characteristics of senescence (termed pre-senescence). A third is the terminally senescent state in which the majority of cells express SA-b-gal and have acquired an enlarged, attened morphology with a well-de®ned nucleus (Jarrard et al., 1999) . Our results demonstrate that the cellular events signaling proliferation arrest at presenescence are distinct from those involved in the maintenance of the terminally-senescent state. Furthermore, we demonstrate that p57 can play a novel role in the induction of senescence and its loss appears to be selected for in cells which have bypassed senescence. Since the cellular pathways that induce growth-arrest are likely to be encountered by tumors, this study provides insight into some of the barriers that prostate and bladder tumors must overcome in the multi-step development of cancer.
Results
Characterization of human prostate epithelial and uroepithelial growth and senescence in vitro HPEC and HUC explants when placed on collagen dishes give rise to epithelial cells with basal cell characteristics (Jarrard et al., 1999) . Based on trypan blue exclusion counting, and calculating plating eciency, HPECs and HUCs exhibit similar growth curves (data not shown). After 3 ± 4 passages, approximately 30 ± 40 population doublings, proliferation terminates (Rezniko et al., 1994) . Cells at this presenescent period appear morphologically identical to proliferating cells, yet have lost their proliferative capacity. Twelve per cent of cells express minimal amounts of SA-b-gal activity (Figure 1 ). Typically 1 ± 2 weeks after this point cells acquire the senescent To characterize cell-cycle parameters in our culture system we performed¯ow cytometry on proliferating, pre-senescent and terminally-senescent cells stained with propidium iodide. Proliferating HPECs contained 14% of cells in S phase (Figure 2 ), while pre-senescent and terminally-senescent cells contained consistently fewer cells in S phase (7.0 and 6.8%, respectively). The terminally-senescent population contained 9.2% more cells in G0/1 than proliferating cultures, suggesting the terminal growth arrest is G0/1 speci®c. A sub-G0/1 peak was not observed, indicating the absence of aneuploid and apoptotic cells. Similarly, we found only a small number of tetraploid cells (50.1%) in senescent cultures. Thus, pre-senescent cells displayed a cell cycle pro®le similar to terminally-senescent cells, although they retained morphological and biochemical (SA-b-gal negative) characteristics of the proliferative population.
Cdk2-associated kinase activity is reduced at pre-senescence Our data and other studies demonstrate senescent HPECs typically arrest in the G0/1 phase (Sandhu et al., 2000) . Maintaining cyclin E:cdk2 and cyclin A:cdk2 activity permits passage through the G1 restriction point . Cdk2-associated kinase levels were assayed in cdk2 immune complexes using histone HI as a substrate (Figure 3 ). Proliferating cells contained a threefold higher level of cdk2 kinase activity than pre-and terminally-senescing HPECs. No further decrease in cdk2-associated activity occurred as cells proceeded from pre-to terminal-senescence. Thus pre-senescent cultures are arrested in G0/1, and these ®ndings suggest decreased cdk2-associated kinase activity contributes to this cell cycle arrest.
Alterations in cell cycle related proteins
To understand those molecular changes that lead to the pre-senescent cell cycle arrest, steady-state levels of cdk inhibitors and their associated cyclins and cdks involved in the G1 to S transition were analysed by Figure 2 Cell-cycle pro®le of (a) proliferating, (b) pre-senescent and (c) terminally-senescent human prostate epithelial cells. Few cells are in S phase at pre-senescence and become arrested at G0/ G1 at terminal-senescence. Cells were stained with propidium iodide and sorted by¯ow cytometry. 10 000 gated events were collected and the percentage in the G1/0, S, G2 phase of the cell cycle ®t with MODFIT software Figure 3 Reductions in Cdk2-associated activity in pre-and terminally-senescent HPECs. Cdk2 immune complexes were precipitated from equal amounts of proliferating (P), presenescent (PS) and terminally-senescent (TS) HPEC extracts and incubated with histone HI and radiolabeled ATP. Proliferating extract was also precipitated with normal rabbit serum (NRS) as a negative control. Reactions were separated by SDS ± PAGE, dried and imaged (a). Twenty-®ve mg of the same extracts used in (a) were separated by SDS ± PAGE and blotted with the same cdk2 antibody to reveal the steady-state cdk2 protein levels (b). PhosphorImager analysis was used to quantitate relative kinase activity. The results are shown as a percentage of the proliferating HPEC kinase activity corrected by background subtraction (c) Figure 4 Western analysis of CDKIs and G1-S cell cycle-related gene products performed on serially passaged HPECs and HUCs. Protein extracts of proliferating, pre-senescent and terminally senescent (a) HPECs and (b) HUCs were separated by SDS ± PAGE and blotted with antibodies to speci®c genes involved in the G1 to S transition. The expression patterns were grouped based on whether expression decreased (top), increased (middle), or transiently increased then decreased (bottom) during passage to terminal senescence. Representative blots from multiple independent HPEC cultures and HUC cultures are shown. Diminished PCNA expression indicates proliferation slowing with increasing time in culture. a-tubulin is included on all blots as a loading control Western blot analysis in proliferating, pre-senescent and terminally-senescent HPECs (Figure 4a ). We found that changes in gene expression could be divided into four classes. One pattern was a steady increase in the levels of the cdk inhibitor p16 with time in culture. A second was a decrease in the levels from proliferation to senescence for pRB, cyclin D1, p19, p27 and PCNA. Not only did pRb levels decline, but the ratio of the inactive hyper-phosphorylated form to the active hypophosphorylated form declined (Figure 4a) . A third group, consisting of cdk2, cdk4, cdk6, cyclin E and p57, did not display signi®cant alterations in protein expression with passage in culture. We were unable to detect p18 at the protein level (data not shown). Finally, a subset of genes were upregulated during the pre-senescent, growth-arrested period and decreased at terminal-senescence to levels found in proliferating cells. Proteins in this class included the transcription factor and tumor suppressor p53 and two cdk inhibitor proteins, p21 and p15. These genes appear important in the cellular arrest prior to terminal senescence, yet are not expressed at high levels during terminal senescence.
To determine if those observed changes in cell cycle proteins were speci®c to prostate epithelial cell senescence or could be found during senescence in other epithelial cell types we analysed human uroepithelial cells. The progression to senescence in HUCs is temporally and morphologically similar to HPECs (Rezniko et al., 1996) . Western blot analysis of uroepithelial cell extracts demonstrated protein level alterations consistent with prostate epithelial cells (Figure 4b ). The only dierence found was the observation that p57 levels steadily increased as HUC cells progressed to senescence. Expression of p57 is tissue speci®c and has been associated with dierentiation in some cell systems (Dyer and Cepko, 2000; Reynaud et al., 2000) .
Altered expression of cyclin-dependent kinase inhibitors in immortalized tumorigenic and non-tumorigenic prostate cell lines
To determine if genes upregulated at the senescence growth arrest are altered with immortalization, we generated a series of HPV16 E6 and E7 immortalized lines from normal HPECs. Several genes important in bypassing senescence, including p16, p21, and genomic regions on chromosomes 20, have been characterized utilizing the HPV16 oncoproteins (Burkhart et al., 1999; Fanton et al., 2001; Savelieva et al., 1997) . In addition to using HPV immortalized lines, we have also examined prostate cancer cell lines to extend the implications of our ®ndings. These lines are not only immortal but tumorigenic, thus they are useful although less speci®c for examining the immortalization process. Western blot analysis was performed to detect steady-state levels of pRb, p16, p15, p57, p21 and p53. To bypass senescence, HPV16 E7 binds and inactivates pRB, while in genomically unstable HPV16 E6 cells, in which p53 is inactivated, the p16 gene is deleted or methylated (Jarrard et al., 1999) . Additionally, inactivating the p53 pathway may be important for bypassing senescence as HPV16 E6 targets p53 for degradation. Western blot analysis showed that HPV16 E7 infected cells expressed large amounts of p16 (Figure 5a ), possibly due to the absence of functional pRB (Hara et al., 1996) . HPV16 E6 lines did not express p16 (Figure 5a ). Consistent with a role in senescence growth arrest, p53 and p21 were not expressed in E6 lines. Both p21 and p53 were present in HPV16 E7 immortalized lines, however p21 pathway is non-functional as E7 binds the carboxy-terminus of p21 and prevents association with cyclin:cdk complexes (Funk et al., 1997; Xiong et al., 1996) . Thus, in the immortal cell lines and in prostate cancer lines tested, either p16 or pRb expression is absent, and p53 and p21 are inactive.
HPV16 E7 lines consistently showed reduced p57 expression compared to the HPV16 E6 lines and normal HPECs (Figure 5b ). HPV16 E6 lines expressed p57 at levels similar to those found in proliferating HPECs. None of the prostate cancer cell lines examined expressed p57 (Figure 5c ). These results suggest that downregulating p57 may be important for bypassing senescence and in the tumorigenic phenotype. HPV16 E6 and E7 lines expressed p15 at minimally detectable levels, markedly lower than levels seen in proliferating HPECs. Only 3/6 immortalized prostate tumor lines expressed p15 (Du145, PC-3 and PPC-1). Thus, those genes found to have elevated expression at pre-senescence, p15, p16, p21, p53 and p57, were frequently altered in immortalized cell lines. Western analysis for pRB, p16, p53 and p21 was carried out as described above on protein extracts of three independent sets of HPV16 E6 or E7 immortalized HPECs. HPV16 E7 infected cells express high levels of p16 (a), mainly due to the absence of functional pRB. Western analysis was also performed to detect and compare levels of p15 and p57 to proliferating and terminally-senescence HPECs in (b) HPV16 E6/E7 immortalized cells and (c) prostate cancer cell lines. P, proliferating; TS, terminally-senescent
Overexpression of p57 induces a senescent-like phenotype in prostate cancer cells
The elevation of p57 at the senescence growth arrest and the downregulation of p57 levels in immortalized cells suggested this gene plays a role in the induction of senescence. To determine if p57 could recapitulate features of senescence, p16, used as a positive control, and p57 were individually cloned into a vector that co-expressed enhanced green¯uorescence protein (GFP). These constructs were separately transfected into the PPC-1 prostate cancer cell line and GFP positive cells were sorted at 2 days post-transfection. Positive cells were replated and, at 5 days posttransfection, analysed for senescence by morphology, G0/G1 arrest, SA-b-gal staining, and collagenase (a senescence marker) induction.
Cells transfected with p16 and p57 became enlarged and¯attened adopting a senescent morphology when compared to vector-only cells (Figure 6a) . Similarly, p16 and p57 overexpressing cells arrested at G0/G1 ( Figure  6b ). Marked staining for SA-b-gal, however, was negative at this timepoint for both vectors. Another marker commonly associated with senescence is the expression of collagenase (Young and Smith, 2001) . Quantitative RT ± PCR (qRT ± PCR) was performed on cDNA synthesized from sorted cells at 5 days posttransfection. Collagenase expression was induced over 500-fold in p16 and p57 expressing cells (Figure 6c) . Thus, p57 overexpression recapitulates several features of the senescence arrest in immortal cells.
Discussion
In the current study, we demonstrate that a subset of cyclin-dependent kinase inhibitors are upregulated at the growth arrest prior to establishment of the mature senescence phenotype in normal human prostate epithelial and urothelial cells. We believe this to be an important point in the proliferative life of a cell and is phenotypically distinct from terminal senescence. The cyclin-dependent kinase inhibitors p15 and p21, as well as p53, were all consistently elevated at the pre-senescence time point. Expression returned to baseline levels observed in proliferating cells at terminal senescence. Elevating levels of p16, and p57 in HUCs, also may contribute to the growth arrest seen prior to terminal senescence. Notably, the only cell-speci®c dierence we identi®ed over the course of HUC and HPEC lifespan was in p57 expression. This variation may re¯ect an additional dierentiation pathway that is required to induce the senescence phenotype in HUCs despite similar culture conditions. Thus, multiple CDKIs, several which are upregulated prior to terminal senescence, contribute to the proliferation block seen in aging cells and would be required to be bypassed during lifespan extension.
The CDKIs transiently upregulated at pre-senescence, p15, p21 and p53, appear to play a role in the induction of senescence in our model and have been shown to regulate senescence when expressed in mortal cells. The induction of p15 occurs in mouse embryo ®broblasts with proliferative aging and in cells that fail to inhibit p15INK4b accumulation, immortalization does not occur (Staller et al., 2001) . Although p15 binds Cdk4/6, similar to p16 function, its expression is unrelated to the presence of functional pRb. Therefore, p15 loss does not correlate with p16 status suggesting it has a distinct function (Herman et al., 1996) . Similar to p15, altering p21 expression modulates the lifespan of normal cells as p21 overexpression leads to premature senescence in human ®broblasts, and cells lacking p21 have an extended lifespan (McConnell et al., 1998; Vogt et al., 1998) . The tumor suppressor p53 can transcriptionally activate p21 and accumulating data suggest it is a key regulator in the induction of senescence (Itahana et al., 2001 ). In Figure 6 A senescence-like phenotype is induced by p57 overexpression. PPC-1 cells were transfected with the GFP expressing pLSG vector containing p16, p57 or vector only. GFP positive cells were sorted at day 48 h, re-plated and analysed at day 5 post-transfection. Cells expressing p16 or p57 appeared¯attened and enlarged compared to vector only (a). Flow cytometry analysis of GFP expressing cells demonstrated a G0/G1 cell cycle block in cells expressing p16 or p57 (b). Levels of collagenase, a marker of senescence, mRNA were determined by qRT ± PCR and compared to vector only cells. The graph depicts fold induction from the vector only cells + standard deviation mice, disruption of the p53 pathway alone is sucient to confer immortalization (Kamijo et al., 1997) . Human cells are more resistant to bypassing senescence requiring the inactivation of additional, perhaps redundant, pathways (Jarrard et al., 1999) . These data support a model whereby several signaling pathways, upregulated at pre-senescence, are critical in the`molecular switch' that initiates subsequent senescence growth arrest.
As cells progressed toward pre-senescence, the balance between positive and negative cell cycle regulators changed to an inhibitory environment favoring decreased cdk activity. The combined eect of elevated p15, p16 and diminishing cyclin D1 levels markedly reduce cdk4/6 activity . We demonstrate low cdk2 kinase activity is another indicator of pre-senescent cells. Reductions in cdk2 activity at pre-senescence may be attributed directly to elevated levels of p21. However, at terminal senescence, high levels of p21 were not sustained, even though cdk2-associated activity remained unchanged from pre-senescence. The combined eects of p16 increases and decreases in cyclin D1 levels appear to shift the existing CIP/KIP family members from cyclin D:cdk4/6 to cyclin E:cdk2 complexes (Cheng et al., 1999) . Thus, p16 maintains the cell cycle arrest directly through cdk4/ 6 interactions or indirectly by displacing CIP/KIP family members from cyclin D:cdk4/6 to cyclin E:cdk2 complexes.
In addition to p16 induction and cyclin D1 repression in our model, what mechanisms maintain cells in a senescent state? A series of pathways may be sequentially engaged to arrest growth, alter morphology and lock cells in a terminally dierentiated state. In addition to changes in the cell cycle, other irreversible changes found at terminal senescence include alterations in the nuclear and cellular cytoskeleton, increased lysosomal content (i.e. activation of SA-b galactosidase), and decreased rates of protein synthesis and degradation (Campisi, 2000) . Genes involved in these pathways, for example RhoB, a gene we ®nd consistently upregulated at senescence (data not shown), may be candidates for maintaining terminal senescence.
The observation that p57 is upregulated in senescence and can induce features of senescence is novel. p57 is a unique member of the CIP/KIP family as it displays genomic imprinting and is expressed solely from the maternal allele (Taniguchi et al., 1997) . We demonstrate p57 expression to be elevated with progressive passages in HUC cultures. We further demonstrate that the induction of p57 expression in p57 non-expressing cancer cells results in a senescence-like phenotype similar to p16 induction. In astrocytoma cells, p57 induction can induce cellular arrest and a senescent phenotype (Tsugu et al., 2000) . Not all features of senescence, speci®cally SA-b galactosidase expression, were able to be induced with p57 expression. This suggests these immortalized cells may have lost this terminal senescence feature. Notably, SA-b galactosidase induction appears dicult to generate in many immortalized cell lines (Chang et al., 1999) .
If senescence genes such as p57, p15, p21 and p16 pose a block for extended lifespan, then we would postulate their expression should be frequently altered in cells that have bypassed senescence. Our data supports this hypothesis. With regard to p57, we ®nd a reduction or loss of expression when non-tumorigenic, immortalized cells are generated and in prostate cancer cell lines. In human mammary epithelial cells immortalized using benzo(a)pyrene, full immortalization was associated with a distinct loss of p57 expression (Nijjar et al., 1999) . However, an exception is our ®nding that p57 levels remain unaltered in HPV16 E6 immortalized lines. Potentially, either the loss of p53 and p21 in these lines bypasses the need to downregulate p57 or the E6 oncoprotein indirectly blocks p57 function.
It is important to note that in HPECs and HUCs, senescence is generated via telomere-independent, rather than telomere-dependent, mechanisms . Since an extended number of population doublings is required to reach a critical telomere length, telomere-independent mechanisms may be more applicable to in vivo senescence in normal tissues and cancer. Senescent cells have been identi®ed in human tissues including the dermis of aged individuals (Dimri et al., 1995) and in benign prostatic hyperplasia, a hyperproliferative disorder of the prostate (Choi et al., 2000) . Pathways that induce senescence in these tissues include oxidative stress, altered basement membranes, as well as cellular DNA and protein damage. Similarly in culture, the high oxygen tension and altered growth and attachment factors contribute to the onset of senescence (Sherr and DePinho, 2000) . Our data and others (Romanov et al., 2001 ) would support this model as being a biologically relevant representation for the senescence block that cancer cells must overcome in the multi-step development of the malignant phenotype.
From a therapeutic standpoint, the re-introduction of senescence may be useful as a tumor suppression mechanism. Drugs that reintroduce senescence in tumor cells (Chang et al., 1999) may be especially applicable to prostate cancer, a slowly proliferating disease commonly diagnosed in elderly men. Furthermore, many of these novel senescence pathways are targeted in the development and progression of human prostate and bladder cancer. The p16/pRb pathway is altered in 85% of primary prostate cancers (Jarrard, submitted) and p57 expression is downregulated in one-third of primary bladder cancers (Oya and Schulz, 2000) . Finally, myoinvasive, aggressive TCCs that bypass senescence have alterations in p53 function, and show either p16 loss or pRb alteration (Sarkar et al., 2000) . The identi®cation of additional novel senescence pathways will assist in the development of these translational studies.
Materials and methods

Tissue samples/cell culture
Prostate tissue was obtained from men (ages 44 ± 66) undergoing cystoprostatectomy. Biopsies con®rmed no cancer was present. Ureteral tissue was obtained from kidneys undergoing transplantation. All tissues were obtained at the University of Wisconsin Hospitals and Clinics under an approved IRB protocol. All cells are maintained in Ham's F-12 media (Life Technologies, Inc.) supplemented with regular insulin, 0.25 units/ml; hydrocortisone, 1 mg/ml; human transferrin, 5 mg/ml; dextrose, 2.7 mg/ml; non-essential amino acids, 0.1 mM; penicillin, 100 units/ml; streptomycin, 100 mg/ml; L-glutamine, 2 mM; cholera toxin, 10 ng/ml; bovine pituitary extract, 25 mg/ml and 1% FBS (Rezniko et al., 1987) . Prostate epithelial cultures were established essentially as described (Jarrard et al., 1999) . Prostate tissues were minced with a scalpel and digested in a solution containing 500 U/ml collagenase (Sigma) and plated on collagen-coated plates. Cells were passaged routinely when con¯uent with trypsin-EDTA. HUC cultures were established as previously described (Rezniko et al., 1983) by mincing ureter epithelium and placing on collagen-coated plates. Cells were maintained as described for HPECs. Proliferating cells for this study were harvested 2 days following ®rst passage. Pre-senescent cells were analysed when cell growth ceased, 1 ± 5% of all cells appeared morphologically rounded,¯attened and enlarged with a well-de®ned nucleus, and SA-b-gal expression was negative. Terminally senescent cells were harvested when 450% appeared morphologically senescent and expressed high levels of SA-b-gal. Triplicate cultures from separate specimens were analysed from both the prostate and urothelial tissues.
All prostate cancer cell lines were grown in RPMI 1640 (Life Technologies, Inc.) supplemented with 7% FBS.
Transformation of HPECs with HPV16 E6 and/or E7
Generation and characterization of these lines have been described (Jarrard et al., 1999) . Brie¯y, retroviruses carrying either the HPV16 E6 and/or E7 gene(s) (received from Dr D Galloway, Seattle, WA, USA) were prepared (Halbert et al., 1991) . Subcon¯uent proliferating HPECs were infected with 10 3 ± 10 5 infectious viral units at pre-passage (*5610 5 cells per 100-mm dish) in 3 ml of 1% FBS, F-12+containing 4 mg/ml polybrene (Sigma). The virus was then removed after 6 h, and selection with 50 mg/ml of G418 (Life Technologies, Inc.) as performed for a minimum of 7 days. Infected cell lines express E6 or E7 transcripts and, based on Western analysis, do not express p53 and pRB, respectively. All immortalized lines are maintained in 1% FBS F-12+. All lines have been passaged over 60 times indicating their immortality.
Prostate cancer cell transfection and cell sorting
Full-length human p16 and p57 (obtained from Joan Massague) cDNA was cloned into the retroviral expression vector pLSG. This vector expresses GFP from the SV40 promoter and the gene of interest from the LTR promoter. PPC-1 cells were plated in 6-well dishes (2610 5 /well) and transfected with Eectene (Qiagen). Two days post-transfection, cells were trypsinized and GFP positive cells collected by¯ow cytometry using the FACS Calibur (Becton Dickinson). Transfection rates varied between 22 and 35%. Sorted cells were plated for 3 additional days prior to analysis.
Quantitative RT ± PCR analysis
Total RNA was isolated using the RNeasy RNA isolation kit (Qiagen) and 1 mg was used to prepare cDNA. Quantitative RT ± PCR was performed by monitoring in real time the increase in¯uorescence of the SYBR Green dye as described using a iCycler detection system (Bio-Rad) (Morrison et al., 1998; Wittwer et al., 1997) . For comparison of transcript levels between samples, a standard curve of cycle thresholds for several serial dilutions of a cDNA sample was established and then used to calculate the relative abundance of each gene. Values were then normalized to the relative amounts of 18 S cDNA, which were obtained from a similar standard curve. All PCR reactions were performed in duplicate. Sequences of primers used for PCR analysis are available upon request.
SA-b-Gal staining
Cells growing in collagen-coated p35 dishes were washed twice in 16PBS and ®xed in a PBS buered solution of 2% paraformaldehyde/0.2% paraformaldehyde for 5 min. Cells were washed again in 16PBS and stained 16 h at 378C in a solution as described (Dimri et al., 1995) . Cells were counted at 2 h and at 16 h and graded as positive if blue nuclear and cytoplasmic staining was displayed.
Flow cytometry
Cells were harvested by trypsin-EDTA, washed in 16PBS, re-suspended in solution containing 0.5% Nonidet and 250 mg/ml RNase A and incubated at 378C for 5 min. Propidium iodide (10 mg/ml) was added and FL2 area was analysed on a FACScan (Becton Dickinson). Cells were analysed for cell cycle position using MODFIT software.
Cdk2-associated kinase activity assay
Cdk2-associated kinase assays were performed as described previously (Lissy et al., 1998) . Cells were harvested by trypsin-EDTA and washed in 16PBS. Protein was extracted by freeze thawing three times in ELB buer (50 mM HEPES pH 7.2, 1 M, 250 mM NaCl, 2 mM EDTA, 0.5% NP-40, 1 mg/ml Aprotinin, 1 mg/ml leupeptin, 50 mg/ml PMSF). Protein extracts were quanti®ed using the Bradford assay. Whole cell extracts, 200 mg, were pre-cleared with Zysorbin (Zymed) and protein A Sepharose beads (Pharmacia) in ELB. After 1 h rotating at 48C and 10 min of centrifugation, 2 mg of rabbit anti-cdk2 antibody (SC-163, Santa Cruz) was added with protein A Sepharose beads and incubated 1 h rotating at 48C. Immune complexes were washed three times in ELB and twice in kinase buer (50 mM HEPES, pH 7.5, 10 mM MgCl 2 ). Kinase reactions consisted of 2 mg of Histone HI (Sigma), 50 mM ATP, 5 mCi [g-32 P]ATP (Amersham) in kinase buer. Reactions were incubated 30 min at 308C, stopped by the addition of 2X SDS sample loading buer and separated on 13.5% polyacrylamide gels. The gels were dried, exposed to a PhosphorImager storage screen (Molecular Dynamics) and imaged with a STORM PhosphorImager (Molecular Dynamics).
